These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20606192)

  • 1. State generic substitution laws can lower drug outlays under Medicaid.
    Shrank WH; Choudhry NK; Agnew-Blais J; Federman AD; Liberman JN; Liu J; Kesselheim AS; Brookhart MA; Fischer MA
    Health Aff (Millwood); 2010 Jul; 29(7):1383-90. PubMed ID: 20606192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
    Lewis JH; Schonlau M; Muñoz JA; Asch SM; Rosen MR; Yang H; Escarce JJ
    N Engl J Med; 2002 Mar; 346(11):830-5. PubMed ID: 11893795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicaid prescription limits: policy trends and comparative impact on utilization.
    Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA
    BMC Health Serv Res; 2016 Jan; 16():15. PubMed ID: 26772962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipitor goes generic: business as usual or more big business?
    Gill L; Santa J; Peter DL; Keehn J
    Ann Intern Med; 2012 Jun; 156(12):892-3, W313. PubMed ID: 22711082
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of state-level pharmacist regulations on generic substitution of prescription drugs.
    Song Y; Barthold D
    Health Econ; 2018 Nov; 27(11):1717-1737. PubMed ID: 29992674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic atorvastatin and health care costs.
    Jackevicius CA; Chou MM; Ross JS; Shah ND; Krumholz HM
    N Engl J Med; 2012 Jan; 366(3):201-4. PubMed ID: 22149736
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
    Fischer MA; Avorn J
    Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
    Kelton CM; Chang LV; Kreling DH
    Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brand-name versus generic.
    Copeland KR; Boccuzzi SJ
    Health Aff (Millwood); 2007; 26(4):1198-9; author reply 1199. PubMed ID: 17630468
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicaid payment for generic drugs: achieving savings and access.
    Peters CP
    Issue Brief George Wash Univ Natl Health Policy Forum; 2010 Sep; (839):1-16. PubMed ID: 20928958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries for patients. Potential savings with substitution of generic drugs for brand-name drugs.
    Ann Intern Med; 2005 Jun; 142(11):I30. PubMed ID: 15941691
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic atorvastatin and health care costs.
    Kennally WC
    N Engl J Med; 2012 Apr; 366(15):1451; author reply 1451. PubMed ID: 22494136
    [No Abstract]   [Full Text] [Related]  

  • 19. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
    Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.